AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9279183 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster at month 60
Number of subjects: 167
Study 8351603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 83
Study 8351603 — intervention group
Group type: COMPARATOR
Intervention: U-shaped retractor
Number of subjects: 83
Study 3034032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 6
Study 3034032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29477098 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band blue light (BLUE, 100 lx, irradiance 1.0 W/m2)
Number of subjects: 45
Study 29477098 — intervention group
Group type: COMPARATOR
Intervention: Bright white-light treatment (BLT, 10 000 lx, irradiance 31.7 W/m2)
Number of subjects: 45
Study 27388352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-E-diffused polyethylene cemented cup
Number of subjects: 50
Study 27388352 — intervention group
Group type: COMPARATOR
Intervention: Argon gas-sterilised polyethylene cemented cup (control group)
Number of subjects: 50
Study 25253184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 400 mg/die
Number of subjects: 100
Study 21790446 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment (50 mg for 5 days, then 75 mg for 7 days)
Number of subjects: 48
Study 21790446 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment
Number of subjects: 48
Study 21790446 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 48
Study 20843344 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary provided at 1 month following critical care discharge
Number of subjects: 352
Study 20843344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICU diary)
Number of subjects: 352
Study 18686772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B Triumph
Number of subjects: 45
Study 18686772 — intervention group
Group type: COMPARATOR
Intervention: Sonicare FlexCare
Number of subjects: 45
Study 15929954 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 3 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin once daily for 5 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg for 3 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin for 5 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin for 5 days
Number of subjects: 2
Study 15929954 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate for 10 days
Number of subjects: 2
Study 12642969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefotiam intravenously 30 min to 4 h before tonsillectomy
Number of subjects: 50
Study 12642969 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg cefuroxime axetil orally 1 to 6 h before tonsillectomy
Number of subjects: 50
Study 10579253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 1 microg/kg/min (group A, n = 9)
Number of subjects: 18
Study 10579253 — intervention group
Group type: COMPARATOR
Intervention: 0.90% saline as control (group B, n = 9)
Number of subjects: 18
Study 8907443 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (three times per week for approximately 1 hour per session for 16 weeks)
Number of subjects: 0
Study 1872271 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 15
Study 1872271 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 15
Study 1872271 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg and 10 mg
Number of subjects: 15
Study 1872271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30932877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression (IC) of MTrPs
Number of subjects: 53
Study 30932877 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 53
Study 28109492 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual materials used at home
Number of subjects: 82
Study 28109492 — intervention group
Group type: COMPARATOR
Intervention: Speech pathology treatment on-site without audiovisual materials
Number of subjects: 82
Study 25588704 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4∗22 carriers
Number of subjects: 186
Study 25588704 — intervention group
Group type: COMPARATOR
Intervention: CYP3A4∗1/∗1 carriers
Number of subjects: 186
Study 25588704 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 genotype effect on Tac Co/dose
Number of subjects: 186
Study 24302181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 24302181 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanyl
Number of subjects: 0
Study 21332383 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg NOMAC/1.5 mg E(2) (n = 9)
Number of subjects: 41
Study 21332383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg NOMAC/1.5 mg E(2) (n = 10)
Number of subjects: 41
Study 21332383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg NOMAC/1.5 mg E(2) (n = 10)
Number of subjects: 41
Study 21332383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg NOMAC alone (n = 9)
Number of subjects: 41
Study 19695795 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic in situ decompression
Number of subjects: 34
Study 19695795 — intervention group
Group type: COMPARATOR
Intervention: Open in situ decompression
Number of subjects: 34
Study 17484155 — intervention group
Group type: EXPERIMENTAL
Intervention: Superbrush
Number of subjects: 34
Study 17484155 — intervention group
Group type: COMPARATOR
Intervention: Elmex interX
Number of subjects: 34
Study 17484155 — intervention group
Group type: COMPARATOR
Intervention: Patients' own toothbrushes
Number of subjects: 34
Study 15710810 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL conjunctival irrigation of 5% povidone-iodine
Number of subjects: 200
Study 15710810 — intervention group
Group type: COMPARATOR
Intervention: 2 drops of 5% povidone-iodine on the conjunctiva
Number of subjects: 200
Study 12173955 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) knee extension
Number of subjects: 32
Study 12173955 — intervention group
Group type: COMPARATOR
Intervention: Leg press exercises
Number of subjects: 32
Study 9860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium inhalation solution mixed into a water‐based emollient cream at a final concentration of 0.21% for 1 month (phase I)
Number of subjects: 26
Study 9860040 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month (phase II)
Number of subjects: 26
Study 9860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium inhalation solution mixed into a water‐based emollient cream at a final concentration of 0.21% after crossover
Number of subjects: 26
Study 9860040 — intervention group
Group type: COMPARATOR
Intervention: Placebo after crossover
Number of subjects: 26
Study 7595909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (20 mmol/day)
Number of subjects: 10
Study 7595909 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (220 mmol/day)
Number of subjects: 10
Study 7595909 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in plasma atrial natriuretic peptide
Number of subjects: 10
Study 7595909 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal excretion of dopa and dopamine
Number of subjects: 10
Study 7595909 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal haemodynamics and renin-angiotensin-aldosterone system
Number of subjects: 10
Study 2404430 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using 0.125% bupivacaine (B)
Number of subjects: 72
Study 2404430 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using 0.125% bupivacaine with fentanyl 1 micrograms/ml (BF)
Number of subjects: 72
Study 2404430 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using 0.125% bupivacaine with fentanyl 1 micrograms/ml and 1:400,000 epinephrine (BFE)
Number of subjects: 72
Study 2404430 — intervention group
Group type: COMPARATOR
Intervention: Physician-controlled continuous epidural infusion using 0.125% bupivacaine (CEI)
Number of subjects: 72
Study 320807 — intervention group
Group type: EXPERIMENTAL
Intervention: HC 20-511 (2.0 mg single dose or two times 1.0 mg for 3 days)
Number of subjects: 24
Study 320807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 320807 — intervention group
Group type: COMPARATOR
Intervention: Clemastin (Tavegyl)
Number of subjects: 24
Study 31659850 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited self-sampling kits for home use
Number of subjects: 222
Study 31659850 — intervention group
Group type: COMPARATOR
Intervention: Current screening
Number of subjects: 222
Study 30950680 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 100
Study 30950680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.5% ophthalmic solution
Number of subjects: 100
Study 28850421 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic onset group
Number of subjects: 200
Study 28850421 — intervention group
Group type: COMPARATOR
Intervention: Non-traumatic onset group
Number of subjects: 200
Study 26136133 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 34
Study 26136133 — intervention group
Group type: COMPARATOR
Intervention: Multiple injections (control)
Number of subjects: 34
Study 23968498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite rTMS protocol (left dorsolateral prefrontal, 1,000 stimuli, 20 Hz; left temporoparietal, 1,000 stimuli, 1 Hz; right temporoparietal stimulation, 1,000 stimuli, 1 Hz)
Number of subjects: 50
Study 23968498 — intervention group
Group type: COMPARATOR
Intervention: Single-site rTMS protocol (unilateral stimulation of the temporoparietal cortex, 3,000 stimuli, 1 Hz)
Number of subjects: 50
Study 23968498 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (25 subjects)
Number of subjects: 50
Study 21325963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (LPA)
Number of subjects: 73
Study 21325963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 665
Study 19187902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (Step 1)
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (Step 3)
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (Step 4)
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 665
Study 19187902 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 665
Study 18005442 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinimax (20 mg/ml) administered via intra-rectal route
Number of subjects: 134
Study 18005442 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 134
Study 15159226 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g fish oil (1.5 g EPA and 1.0 g DHA) daily for 12 weeks
Number of subjects: 84
Study 15159226 — intervention group
Group type: COMPARATOR
Intervention: 4.0 g olive oil (control) daily for 12 weeks
Number of subjects: 84
Study 11194073 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital 12-lead electrocardiograms and initiation of thrombolytic therapy
Number of subjects: 0
Study 11194073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education to reduce delay in recognizing symptoms and seeking assistance
Number of subjects: 0
Study 11194073 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate use of 911 systems and improving technological 911 support
Number of subjects: 0
Study 11194073 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict and comprehensive definition of criteria for heart centers
Number of subjects: 0
Study 9784080 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone
Number of subjects: 15
Study 9784080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8164931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromopertubation
Number of subjects: 500
Study 8164931 — intervention group
Group type: COMPARATOR
Intervention: No chromopertubation
Number of subjects: 500
Study 3075725 — intervention group
Group type: EXPERIMENTAL
Intervention: Viqualine dihydrochloride
Number of subjects: 10
Study 3075725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31231969 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' judgment of treatment response and remission using parent-reported SCARED after acute treatment
Number of subjects: 436
Study 31231969 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' judgment of treatment response and remission using parent-reported SCARED after follow-up care
Number of subjects: 436
Study 31231969 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of parent-reported SCARED in therapists' judgment
Number of subjects: 436
Study 31231969 — intervention group
Group type: COMPARATOR
Intervention: Therapists' ratings of anxiety severity and improvement
Number of subjects: 436
Study 27642760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic planning condition (DPC)
Number of subjects: 338
Study 27642760 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual planning condition (IPC)
Number of subjects: 338
Study 27642760 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 338
Study 26427889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch ad libitum
Number of subjects: 194
Study 26427889 — intervention group
Group type: COMPARATOR
Intervention: No lunch
Number of subjects: 194
Study 26427889 — intervention group
Group type: EXPERIMENTAL
Intervention: High postprandial cortisol increase after lunch
Number of subjects: 194
Study 26427889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postprandial cortisol increase after lunch
Number of subjects: 194
Study 23479422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib at 750 mg/day with paclitaxel and trastuzumab (THL)
Number of subjects: 109
Study 23479422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib at 750 mg/day
Number of subjects: 109
Study 23479422 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and trastuzumab (THL)
Number of subjects: 109
Study 21513847 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg
Number of subjects: 142
Study 21513847 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Number of subjects: 142
Study 21513847 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg
Number of subjects: 142
Study 21513847 — intervention group
Group type: COMPARATOR
Intervention: Non-Japanese patients (control group)
Number of subjects: 142
Study 19317204 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention group
Number of subjects: 52
Study 19317204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 17028377 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc daily for 4 weeks
Number of subjects: 56
Study 17028377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 14769225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin topical drops
Number of subjects: 125
Study 14769225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin topical drops
Number of subjects: 125
Study 14769225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tobramycin topical drops
Number of subjects: 125
Study 11008571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (various techniques)
Number of subjects: 97
Study 8824982 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 8824982 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole
Number of subjects: 0
Study 8824982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 0
Study 1451220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (7.5 IU.ml‐1) with etidocaine
Number of subjects: 150
Study 1451220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (15 IU.ml‐1) with etidocaine
Number of subjects: 150
Study 1451220 — intervention group
Group type: COMPARATOR
Intervention: Plain etidocaine (without hyaluronidase)
Number of subjects: 150
Study 6379307 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1 U/kg/hr) with 33% glucose infusion (0.5 gm/kg/h) and potassium (0.25 mEq/kg/hr)
Number of subjects: 20
Study 6379307 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (control)
Number of subjects: 20
Study 31982605 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg, twice a day
Number of subjects: 44
Study 31982605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30297369 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBA itraconazole (2 65-mg capsules twice a day) under fasting conditions
Number of subjects: 48
Study 30297369 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBA itraconazole (2 65-mg capsules/day) with omeprazole (1 40-mg capsule/day)
Number of subjects: 48
Study 27368067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy (RT), 30 Gy in five fractions to the operative bed with 2- to 3-cm margins.
Number of subjects: 20
Study 27368067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy (RT)
Number of subjects: 20
Study 25365270 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories and sodium menu labelling
Number of subjects: 3080
Study 25365270 — intervention group
Group type: COMPARATOR
Intervention: Calories menu labelling
Number of subjects: 3080
Study 25365270 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories, sodium, and serving size menu labelling
Number of subjects: 3080
Study 22640563 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation (200 μg twice daily)
Number of subjects: 6
Study 22640563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation (250 μg twice daily)
Number of subjects: 6
Study 22640563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1mg/kg once daily)
Number of subjects: 6
Study 22640563 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation (room air twice daily)
Number of subjects: 6
Study 20535764 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned treatment for migraine
Number of subjects: 0
Study 20535764 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned treatment for other chronic diseases
Number of subjects: 0
Study 18853660 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 87
Study 18853660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlide
Number of subjects: 87
Study 18853660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 87
Study 18853660 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Adriamycin, Vincristin, Cyclophosphamide) + Radiation (40 Gy)
Number of subjects: 87
Study 11169943 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, 175 mg/m(2) intravenously over 3 hours on Day 1, followed by leucovorin, 300 mg over 30-60 minutes and 5-fluorouracil, 350 mg/m(2) intravenously on Days 1-3 (Arm A)
Number of subjects: 34
Study 11169943 — intervention group
Group type: COMPARATOR
Intervention: Etoposide, 100 mg/m(2) intravenously on Days 1-3 and carboplatin at an area under the curve of 6 on Day 1 (Arm B)
Number of subjects: 34
Study 9391858 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization therapy after AMI
Number of subjects: 223
Study 9391858 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful recanalization and unimproved MR (BS-)
Number of subjects: 223
Study 9391858 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization and no MR (CS+)
Number of subjects: 223
Study 9391858 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LVDd and LVEDV
Number of subjects: 223
Study 8198723 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic Gel Sheeting (SGS)
Number of subjects: 42
Study 8198723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cica-Care (CC)
Number of subjects: 42
Study 8198723 — intervention group
Group type: COMPARATOR
Intervention: Control areas (untreated)
Number of subjects: 42
Study 3109227 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator
Number of subjects: 272
Study 3109227 — intervention group
Group type: EXPERIMENTAL
Intervention: streptokinase
Number of subjects: 272
Study 3109227 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group with no treatment)
Number of subjects: 272
Study 31308647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) ventilation
Number of subjects: 102
Study 31308647 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 102
Study 31308647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (NHF and NIV)
Number of subjects: 102
Study 28151818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond (2-octylcyanoacrylate)
Number of subjects: 66
Study 28151818 — intervention group
Group type: COMPARATOR
Intervention: Mastisol (alcohol 23A, gum mastic, storax, and methyl salicylate)
Number of subjects: 66
Study 28151818 — intervention group
Group type: COMPARATOR
Intervention: Mastisol
Number of subjects: 66
Study 28151818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond and Mastisol
Number of subjects: 66